Quantcast

Latest biopharmaceutical Stories

2014-10-23 12:30:38

ROCKVILLE, Md., Oct. 23, 2014 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") today reported on data presented by Dr. Michael Chopp at the Fourth International Symposium on Thymosins in Health and Disease in Rome, Italy. Dr. Chopp reviewed research on the use of Thymosin beta 4 (TB4) as a protective and regenerative agent for nervous system injuries and diseases. He also presented data on the molecular mechanisms underlying TB4's...

2014-10-23 12:29:39

FREMONT, Calif., Oct. 23, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that Ardelyx, together with its development partner, AstraZeneca (NYSE:AZN, LON:AZN), will present tenapanor-related preclinical and clinical results during Kidney Week 2014, the annual meeting of the American Society of Nephrology (ASN). Abstracts of the presentations were published today on...

2014-10-22 23:06:52

With the USA accounting for 34% of the world's pharmaceuticals, certified CNPR Pharmaceutical Sales Reps are needed to promote new products coming down the pipeline. For entry level pharmaceutical sales to meet basic job requirements the NAPSRx's pharmaceutical sales training should be completed before applying. Washington, DC (PRWEB) October 22, 2014 The United States is the world’s largest market for pharmaceuticals and is the world leader in biopharmaceutical research....

2014-10-22 08:31:10

- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform - LA JOLLA, Calif., Oct. 22, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned,...

2014-10-22 08:27:12

NEW YORK, Oct. 22, 2014 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors reducing the potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical...

2014-10-20 08:32:21

Expands rHuPH20 Production SAN DIEGO, Oct. 20, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved new contract manufacturing facilities used in the production of Hylenex(®) recombinant (hyaluronidase human injection). The FDA approved the use of the Cook Pharmica manufacturing facility in Bloomington, Indiana for the production of bulk rHuPH20, the active ingredient used in Hylenex, and the...

2014-10-20 08:27:27

NEW YORK, Oct. 20, 2014 /PRNewswire/ -- Mapp Biopharmaceutical's valiant effort to produce more of their experimental ZMapp(TM) antibody therapeutic to fight the Ebola outbreak will make the public aware of how difficult and time-consuming the production of pharmaceuticals can be, according to Kalorama Information. The healthcare market research publisher said that while some may be taken aback by the three-month production cycle of this compound, those with industry knowledge are...

2014-10-14 23:09:20

Selexis has promoted director of European business development, Marco Bocci, PhD, PharmD, to Vice President, European Licensing and Business Development for Europe. Geneva, Switzerland (PRWEB) October 14, 2014 Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development, has promoted director of European business development, Marco Bocci, PhD, PharmD, to Vice President, European Licensing and Business Development. Bocci...

2014-10-07 08:30:26

IDT Biologika is among the few biopharmaceutical CMOs in Europe to offer a unique combination of sterile liquid dosage forms and vaccines contract manufacturing services LONDON, Oct. 7, 2014 /PRNewswire/ -- Based on its recent analysis of the biopharmaceutical contract manufacturing industry, Frost & Sullivan recognizes IDT Biologika with the 2014 Europe Frost & Sullivan Award for Customer Service Leadership. IDT Biologika's high-quality customer care, best-in-class practices, and...

2014-10-06 12:25:17

NEW YORK, Oct. 6, 2014 /PRNewswire/ -- The FDA's grant of permission of "expanded access" to Tekmira to administer an experimental medicine for Ebola highlights not only the grave threat the disease outbreak presents, but also the difficulty of bringing life-saving products such as vaccines to market, according to Kalorama Information. The healthcare market research publisher studied vaccine production in its recent report, Biopharmaceutical and Vaccine Production Markets....


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin